Shai Mulinari
21 – 30 of 91
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
(
- Contribution to journal › Article
-
Mark
Capitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
(
- Contribution to journal › Article
- 2021
-
Mark
Failure of responsive regulation? : Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry self-regulation and non-transparency : country and company level analysis of payments to healthcare professionals in seven European countries
(
- Contribution to journal › Article
-
Mark
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: A European policy review
(
- Contribution to journal › Article
-
Mark
Drug company payments to General Practices in England: cross-sectional and social network analysis
(
- Contribution to journal › Article
-
Mark
Is there evidence for the racialization of pharmaceutical regulation? : Systematic comparison of new drugs approved over five years in the USA and the EU
(
- Contribution to journal › Article
-
Mark
Sociologisk forskning om covid-19-pandemin : En introduktion
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Sweden
2021)(
- Chapter in Book/Report/Conference proceeding › Chapter in report
-
Mark
Data Transparency and Pharmaceutical Regulation in Europe : Road to Damascus, or Room without a View?
2021) p.63-94(
- Chapter in Book/Report/Conference proceeding › Book chapter